Nunzia Pharmaceutical Corporation is an Emerging Leader in Innovative Pharmaceutical and Nutraceuticals

Nunzia Pharmaceutical Launches a New Version of its Already Acclaimed NUNZIA Nutraceutical. The New Methylated Version Boosts B6, 12 & FA

SAN CLEMENTE, CA, April 16, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nunzia Pharmaceutical Corporation (OTC MKTS: NUNZ), an emerging leader in innovative pharmaceutical and nutraceutical based therapies for the treatment of behavioral anxiety symptoms of Autistic Spectrum of Disorders (ASDs) and other anxiety disorders, is pleased to announce the launch of a new version of its already acclaimed NUNZIA nutraceuticals. The new version is the methylated version.  Why use methylation? Methylation helps rid the body of toxins; it is useful for converting vitamins that are water soluble, into the fat-soluble form. Methylated vitamins are even more important because many people may suffer from a methylation deficiency. Many people are genetically predisposed to having inadequate methylation. For many, B vitamin supplements may not be enough. In the US, as many as 60% of the population has a genetic defect that inhibits the process of turning folic acid into its active component, 5-MTHF, needed for methylation.  The new version is not ready for sale yet, but studies are beginning and the version will be available in 60 to 90 days. Both versions of NUNZIA’s Nutraceuticals will be available direct to consumers through the Company’s website, www.nunziapharma.com. Presently, the acclaimed first generation is available directly to consumers through its website.

NUNZIA provides a highly effective and targeted supplement for a rapidly growing autism market. In 2000, less than 1 in 150 American children were affected by autism, a prevalence that is now 1 in 45. There are 1.4 million children and 700,000 American adults affected with an estimated economic cost of between $11.5 and $60.9 billion per year. 

Current treatments for ASDs have had limited efficacy, with broad acting drugs such as antidepressants, antipsychotics, SSRIs and amphetamines being employed to varying and inconsistent treatment results.  In addition to the unmet treatment needs for ASD’s, NUNZIA also broadly treats a wide range of related anxiety disorders- from ADHD which affects 4.8% of US adults and 8.7% of adolescents; to anxiety disorders (generalized, panic, and phobia related) that impact over a third of US adults and adolescents; and depressive disorders affecting up to 7.1% of the US adult population.